API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Jaypirca (pirtobrutinib) is an oral small molecule, BTK inhibitor which is under phase 3 clinical development for the treatment of chronic/small lymphocytic leukemia & mantle cell lymphoma.
Lead Product(s): Pirtobrutinib
Therapeutic Area: Oncology Product Name: Jaypirca
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
Jaypirca® (pirtobrutinib) is a non-covalent (reversible) BTK inhibitor. It is approved for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Lead Product(s): Pirtobrutinib
Therapeutic Area: Oncology Product Name: Jaypirca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2023
Details:
Jaypirca (pirtobrutinib) is a small molecule and a highly selective non-covalent inhibitor of Bruton’s tyrosine kinase (BTK). Its high selectivity has been associated with lower discontinuation rates due to adverse events and a lower incidence of atrial fibrillation.
Lead Product(s): Pirtobrutinib
Therapeutic Area: Oncology Product Name: Jaypirca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2023
Details:
Jaypirca (pirtobrutinib) is a highly selective, reversible inhibitor of the enzyme BTK. BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including mantle cell lymphoma.
Lead Product(s): Pirtobrutinib
Therapeutic Area: Oncology Product Name: Jaypirca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2023
Details:
Pirtobrutinib (LOXO-305), is an investigational, highly selective, reversible (non-covalent) inhibitor of Bruton's tyrosine kinase (BTK). Pirtobrutinib was developed to reversibly bind BTK, deliver consistently high target coverage regardless of BTK turnover rate.
Lead Product(s): Pirtobrutinib,Venetoclax,Rituximab
Therapeutic Area: Oncology Product Name: LOXO-305
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
Pirtobrutinib (LOXO-305), is an investigational, highly selective, reversible (non-covalent) Bruton's tyrosine kinase (BTK) inhibitor to treat chronic lymphocytic leukemia.
Lead Product(s): Pirtobrutinib
Therapeutic Area: Oncology Product Name: LOXO-305
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
Data will be presented from BRUIN Phase 1b study of pirtobrutinib, an investigational, highly selective, non-covalent (reversible) BTK inhibitor, in combination with venetoclax, a CDK4/6 inhibitor with and without rituximab in relapsed/refractory chronic lymphocytic leukemia.
Lead Product(s): Pirtobrutinib,Venetoclax,Rituximab
Therapeutic Area: Oncology Product Name: LOXO-305
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022